The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

HER3-targeted antibody-drug conjugate shows promise for treatment-resistant solid tumors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

A new targeted cancer drug, DB-1310, is showing early signs of effectiveness in patients with advanced solid tumors that have not responded to standard treatments, particularly those with EGFR-mutant non-small cell lung cancer, according to results from an international clinical trial led by Aaron Lisberg at the UCLA Health Jonsson Comprehensive Cancer Center.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Cancer Policy

Trump administration broke law by canceling DEI research grants, GAO finds

The Government Accountability Office, an independent, non-partisan congressional watchdog agency, found that NIH violated the Impoundment Control Act of 1974 when it cancelled nearly 2,000 research grants in an effort to comply with several of President Donald Trump’s executive orders, including “Ending Radical And Wasteful Government DEI Programs And Preferencing” (The Cancer Letter, Jan 24, 2025).
By Jacquelyn Cobb
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account